Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy

Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy

Fibroblast growth factor receptor 2 (FGFR2) fusions have emerged as a new therapeutic target for cholangiocarcinoma in clinical practice following the United States Food and Drug Administration (FDA) approval of Pemigatinib in May 2020. FGFR2 fusions can result in a ligand-independent constitutive a...

Full description

Bibliographic Details
Main Authors: Alexander Scheiter, Felix Keil, Florian Lüke, Jirka Grosse, Niklas Verloh, Sabine Opitz, Sophie Schlosser, Arne Kandulski, Tobias Pukrop, Wolfgang Dietmaier, Matthias Evert, Diego F. Calvisi, Kirsten Utpatel
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Current Oncology
Subjects:
cholangiocarcinoma
FGFR fusion
NDC80
FRS2
Online Access:https://www.mdpi.com/1718-7729/28/2/112

Internet

https://www.mdpi.com/1718-7729/28/2/112

Similar Items